NiSource (NI) is making headlines this week after securing a green light from the Indiana Utility Regulatory Commission for its NIPSCO Generation LLC (GenCo) declination petition. This regulatory win is anything but routine. It effectively gives NiSource the keys to own, build, and operate power generation assets designed specifically to support Northern Indiana’s booming data center industry. By shielding existing customers from the added costs that come with surging demand, GenCo is not just about meeting new needs, but also about future-proofing the company’s relationships and financial stability.

This development falls into place against a backdrop of steady momentum for NiSource, both on and off the trading floor. Over the past year, the stock has climbed more than 27%, outpacing both peers and broader market indices. Recent months have seen the narrative shift from slimmer short-term gains to renewed optimism, as evidenced by annual revenue and net income growth, and continued investment in infrastructure and cleaner energy upgrades. The approval of GenCo simply adds another gear to this broader growth engine, particularly as demand from data centers and large-scale energy users accelerates.

With the stock outperforming so far this year and GenCo approval potentially opening up new growth avenues, the key question now is whether NiSource is undervalued or if the market is already pricing in this next phase of expansion.

Most Popular Narrative: 3% Undervalued

According to the most widely followed narrative, NiSource is currently undervalued by about 3% compared to its estimated fair value, based on forward-looking earnings and revenue metrics.

Robust infrastructure upgrades and digital efficiencies are reducing costs, expanding margins, and positioning NiSource for sustained earnings and regulated revenue growth.

Curious why analysts are so bullish on NiSource? Discover the bold financial assumptions that separate this stock from the utilities crowd. What are the future profit margins and investment levels powering this story? The answer may surprise you. See what is driving this compelling fair value estimate.

Result: Fair Value of $43.91 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, significant capital needs and accelerating electrification trends could pressure margins and limit growth. These factors may potentially challenge the optimistic outlook for NiSource.

Find out about the key risks to this NiSource narrative.

Another View: Looking Beyond Analyst Price Targets

While many see fair value in NiSource’s current price, our SWS DCF model tells a different story. This approach suggests shares may actually be trading above their true value, which raises doubts about the optimism built into consensus forecasts. Which assessment will prove right as new trends unfold?

Look into how the SWS DCF model arrives at its fair value.

Stay updated when valuation signals shift by adding NiSource to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own NiSource Narrative

Think there’s more to the story, or want to run the numbers yourself? It takes less than three minutes to craft a custom narrative and see how your perspective stacks up. Do it your way

A great starting point for your NiSource research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Winning Investment Ideas?

Don’t miss the chance to spot tomorrow’s top performers while others hesitate. Give yourself an edge by targeting exciting themes shaping the market’s future:

• Uncover potential in small companies reshaping industries with hands-on research into penny stocks with strong financials now gaining market traction.
• Find yield opportunities by reviewing dividend stocks with yields > 3% offering stable returns and attractive annual payouts to strengthen your portfolio in any climate.
• Ride the next big wave in healthcare by investigating healthcare AI stocks transforming diagnostics, patient care, and medical innovation through artificial intelligence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.